Header
 
Login
 

Privatsphäre-Einstellungen

Wir verwenden Cookies auf unserer Website. Einige von ihnen sind unerlässlich, während andere uns helfen, diese Website und Ihre Erfahrungen zu verbessern.

Notwendig Statistik Marketing
Alle auswählen
Auswahl bestätigen
Weitere Einstellungen

Hier finden Sie eine Übersicht aller verwendeten Cookies. Sie können ganzen Kategorien Ihre Zustimmung geben oder weitere Informationen anzeigen und bestimmte Cookies auswählen.

Alle auswählen
Auswahl bestätigen
Notwendig Cookies
Wesentliche Cookies ermöglichen grundlegende Funktionen und sind für die ordnungsgemäße Funktion der Website erforderlich.
Statistik Cookies
Statistik-Cookies sammeln anonym Informationen. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing Cookies
Marketing-Cookies werden von Werbekunden oder Publishern von Drittanbietern verwendet, um personalisierte Anzeigen zu schalten. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen
Zurück

    EMEA and EU Commission – Topical News

    European Commission: Proposal for a Directive amending the Community Code as regards the prevention of entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source

    Dr. Brigitte Friese

    Rechtsanwältin, Wyk-Wrixum auf Föhr (Germany)

    The draft of a Directive amending the Community Code in relation to prevention of entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source envisages to achieve this aim by proposing the implementation of several means:
    • Identification, authenticity and traceability of medicinal products subject to medical prescription shall be guaranteed by introduction of safety features on the outer packaging of such medicinal products.
    • Any persons participating in the legal supply chain will have to be subject to supervision and inspection. A manufacturing authorisation will be necessary for all actors who are involved in the packaging of a medicinal product. Even the “trading of medicinal products” shall be addressed by legislation by imposing on traders express obligations of notification of their activity and regarding recording and instalment of quality and emergency systems.
    • Supervision and inspection of wholesale as well as manufacturing activities including inspection of manufacturing sites in third countries performed by competent authorities shall be enforced. The responsibility of the manufacturer even with respect to falsifications is enlarged. Certificates shall be issued not only for manufacturers, but also for importers and wholesale distributors. The results of inspections shall be entered into a Community database.




    © ECV- Editio Cantor Verlag (Germany) 2009

     

    pharmind 2009, Nr. 3, Seite 435